Methylarginines in Mice with Experimental Atherosclerosis
Male
0301 basic medicine
omega-N-Methylarginine
Poloxamer
Arginine
Atherosclerosis
3. Good health
Mice
03 medical and health sciences
Cholesterol
0302 clinical medicine
Mice, Inbred CBA
Animals
Endothelium, Vascular
Nitric Oxide Synthase
Triglycerides
DOI:
10.1007/s10517-015-3086-3
Publication Date:
2015-11-24T20:31:37Z
AUTHORS (3)
ABSTRACT
We studied the dynamics of indexes for the system of endogenous regulation of NO bioavailability. The content of NO synthase inhibitors (monomethylarginine and asymmetric dimethylarginine) in the blood of mice was measured after intraperitoneal injections of a nonionic surfactant poloxamer 407 for 2 and 14 weeks. The concentrations of both methylarginines in animals with atherosclerosis due to 14-week administration of poloxamer were much higher than in control specimens. The amount of arginine and symmetric dimethylarginine practically did not differ from the control. Poloxamer-induced model of atherosclerosis is characterized by increased content of NO synthase inhibitors. These changes contribute to the development of endothelial dysfunction and atherosclerosis.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (15)
CITATIONS (1)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....